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Summary 
Suppression of experimental autoimmune encephalomyelitis (EAE) in Lewis rats by the oral 
administration of myelin basic protein (MBP) is mediated by CD8 + T cells that can be isolated 
from the spleens of MBP-fed animals. These cells adoptively transfer protection to naive animals 
subsequently immunized with MBP and complete Freund's adjuvant (CFA) and suppress in vitro 
MBP proliferative responses.  Using a transwell system in which the modulator spleen cells from 
MBP-fed animals are separated by a semipermeable membrane from responder cells,  MBP, or 
OVA-specific T cell lines, we have found that cell contact is not required for in vitro suppression 
to occur. In vitro suppression is dependent, however, upon antigen-specific triggering of modulator 
T  cells.  Once antigen-specific triggering occurs, suppression across  the transwell is mediated 
by an antigen-nonspecific soluble factor that equally suppresses  an MBP line or an ovalbumin 
(OVA) line. This phenomenon of antigen-driven bystander suppression was also demonstrated 
in vivo. Specifically, Lewis rats fed OVA which were then immunized with MBP/CFA plus OVA 
given separately subcutaneously were protected from EAE. Animals fed OVA and then immunized 
with MBP/CFA without OVA given subcutaneously were not protected. The protective effect 
of feeding OVA could be adoptively transferred by CD8 + T  cells from OVA-fed animals into 
MBP/CFA plus OVA-injected animals. Feeding bovine serum albumin (BSA) or keyhole limpet 
hemocyanin did not suppress  EAE in animals immunized with MBP/CFA plus OVA. EAE was 
suppressed, however, if BSA was fed and animals then immunized with MBP/CFA plus BSA 
given subcutaneously.  Antigen-driven bystander suppression appears to be an important mechanism 
by which antigen-driven peripheral tolerance after oral administration of antigen is mediated, 
and presumably occurs in the microenvironment accounting for the antigen specificity of suppression 
generated by oral tolerization to antigens. 
A  variety  of mechanisms  have  been  described  for  the 
maintenance of self-tolerance in the host. These include 
clonal deletion (1), clonal anergy (2, 3), and active suppres- 
sion (4; and reviewed in reference 5). We have been studying 
antigen-driven active suppression after oral administration of 
antigens as a tolerance mechanism and as a method to down- 
regulate autoimmune diseases in experimental animals (6-11). 
In the experimental autoimmune encephalomyelitis (EAE)  1 
model, oral administration of myelin basic protein (MBP) 
suppresses clinical, histologic, and immune parameters of the 
disease  (6,  12).  This effect is mediated by CD8 + T  cells, 
which can adoptively transfer protection and suppress in vitro 
proliferative responses (7). Although various mechanisms of 
active suppression have been demonstrated (5,  13), the pre- 
cise mechanism(s) by which T cells mediate suppression re- 
1Abbreviations used in this paper: DTH, delayed-type  hypersensitivity;  EAE, 
experimental  autoimmune  encephalomyelitis;  MBP, myelin  basic protein; 
PPD, purified protein derivative. 
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mains to be defined. The present study uses both an in vitro 
and in vivo model system to examine the mechanism of sup- 
pression mediated by T cells after oral administration of an- 
tigen.  Our results demonstrate that in vitro such cells are 
triggered in an antigen-specific fashion but mediate their effect 
via an antigen-nonspecific suppressor factor. Based on these 
in vitro findings, antigen-driven bystander suppression has 
also been demonstrated in vivo in the EAE model. 
Materials  and Methods 
Animals.  Female  Lewis rats 6-8 wk of age were obtained from 
Harlan-Sprague Dawley Inc.  (Indianapolis, IN).  Animals were 
housed in Harvard Medical School animal care facilities and main- 
tained on standard laboratory chow and water ad libitum. Animals 
were maintained in accordance with the guidelines of the Com- 
mittee on Care of Laboratory Animals of the Laboratory Research 
Council. 
Antigens.  Guinea pig MBP was purified from brain tissue by 
a method modified from Deibler et al. (14) and purity checked by 
gel electrophoresis. OVA and BSA were purchased from Sigma 
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Corp.  (La JoUa,  CA). 
Immunization of Animals.  Animals  were immunized with 25 
#g of MBP in the footpad, emulsified in an equal volume of CFA 
containing 4 mg/ml of mycobacterium tuberculosis (Difco Labs, 
Detroit, MI). For in vivo bystander suppression experiments, 50-300 
#g of the secondary antigens OVA, BSA, or KLH were injected 
subcutaneously in the same footpad in 100 #1 PBS 8 h after pri- 
mary immunization with MBP/CFA. 
ClinicaIEvaluation.  Animals were evaluated in a blinded fashion 
every day for evidence of EAE. Clinical severity of EAE was scored 
as follows:  0, no disease;  1, limp tail;  2, hind limb paralysis;  3, 
hind limb paraplegia,  incontinence; 4, tetraplegia; 5, death. Mean 
maximal clinical severity was calculated as previously described for 
each experimental group (7). Statistical analysis was performed using 
a one-tailed student's t test or a X  2 analysis for comparing incidence 
between groups. 
Induction of Oral Tolerance.  Animals were fed Img MBP, OVA, 
BSA, or KLH dissolved in 1 ml PBS or PBS alone, by gastric intu- 
bation  using  an  18-gauge  stainless  steel  animal feeding needle 
(Thomas Scientific, Swedesboro,  NJ). Animals were fed five times 
(total dose of 5 mg), at intervals  of 2-3 d with the last  feeding 
2 d before immunization. 
Delayed Type Hypersensitivity  (DTH) Testing.  DTH was tested 
by injecting 50 #g of MBP or OVA in PBS, subcutaneously into 
the ear. MBP was injected in the left ear and OVA in the right 
ear in the same animal.  Thickness, in units of 0.01 inch, was mea- 
sured in a blinded fashion, before and 48 h after challenge,  using 
micrometer calipers (Mitutoyo, Utsunomia, Japan). Change in ear 
thickness before and after challenge was recorded for each animal, 
and results were expressed as the mean for each experimental group 
_+  SEM;  each group consisted of five animals. 
Transwell Cultures.  A dual chamber transwell culture system 
(Costar, Cambridge, MA), which is 24.5 mm in diameter and con- 
sists of two compartments separated by a semi-permeable polycar- 
bonate membrane, with a pore size of 0.4/~m, was used. The two 
chambers are 1 mm apart, allowing cells to be coincubated in close 
proximity without direct ceU-to-cell contact. To measure in vitro 
suppression  of proliferative responses  in transwell cultures, 5  x 
104 MBP- or OVA-specific line cells, raised and maintained as pre- 
viously described (15), were cultured with  105 irradiated (2,500 
rad) thymocytes, in 600 #1 of proliferation media in the lower well. 
Spleen cells from orally tolerized rats or controls (fed PBS) were 
added to the upper well (5  x  105 cells in 200 #1). Spleen cells were 
removed 7-14 d after the last feeding, and a single cell suspension 
was prepared by pressing the spleens through a stainless steel mesh. 
MBP and OVA (50 #g/ml) were added in a volume of 20 #1. Be- 
cause modulator cells are separated from responder cells by a semi- 
permeable membrane, they do not require irradiation. In some ex- 
periments, modulator cells were added in the lower well together 
with responder cells, and in these instances  modulator cells were 
irradiated (1,250 tad) immediately before being placed in culture. 
Proliferation media consisted of KPMI 1640 (Gibco Laboratories, 
Grand Island,  NY) supplemented with 2  x  10 -5 M 2-ME,  1% 
sodium pyruvate, 1% penicillin  and streptomycin, 1% glutamine, 
1% Hepes buffer, 1% nonessential amino acids, and 1% autolo- 
gnus serum. Each transweil was performed in quadruplicate. The 
transwells  were incubated at 37~  in a humidified 6% CO2 and 
94% air atmosphere for 72 h. After 54 h of culture, each lower 
well was pulsed with 4 #Ci of [3H]thymidine and at 72 h  split 
and reseeded  to three wells  in a round-bottomed 96-well  plate 
(Costar) for harvesting onto fiberglass filters and counting using 
standard liquid scintillation techniques. Percent suppression =  100x 
(1  -  A  cpm  responders cultured with  modulators/A  cpm  of 
responders). 
Purification of T Cell Subsets.  Depletion of T cell subsets was 
performed by negative selection  using magnetic beads according 
to the modified method of Cruikshank et al. (16). Spleen cells were 
incubated with a 1:100 dilution of mouse anti-rat CD8, or CD4, 
mAbs (clones OX/8 or W3/25 Serotec/Bioproducts, Indianapolis, 
IN) for 30 min on ice, washed twice, and then added to prewashed 
magnetic particles, with an average diameter of 450 # (M-450) with 
goat anti-mouse IgG covalently attached (Dynal Inc., Fort Lee, 
NJ). The quantity of magnetic beads used was calculated as being 
10 times the estimated target cell population. The cells were in- 
cubated with the beads  in 0.5 ml of RPMI  1640 supplemented 
with  10%  FCS  in  a  10  ml round-bottomed test  tube  (Nunc, 
goskilde, Denmark) for 30 min on ice with gentle shaking every 
5 rain. After incubation, the bead/ceU suspension was washed with 
5 ml of medium and cell-mAb-bead complexes were separated from 
unlabeled cells in a strong magnetic field using a magnetic-particle 
concentrator (Dynal-MPC-1) for 2 rain. The supematant was re- 
moved, and the procedure repeated twice to obtain the nonadherent 
fraction.  The  T  cells  in  the  depleted population  were >95% 
CD4+CD8 -  or CD8+CD4 -  as demonstrated by indirect flow 
cytometry. 
Adoptive Transfer  of  Disease Suppression.  Donor rats were fed ei- 
ther 1 mg MBP,  OVA,  or KLH, five times at 2-d intervals  and 
killed 7-14 d after the final feeding.  Spleen cells were harvested, 
and incubated in vitro with the homologous antigen (50 #g/ml) 
in proliferation medium, for 72 h. Cells were injected intraperito- 
neally:  10  s ceils for whole spleen populations or 5-6  x  107 cells 
for CDS- or CD4-depleted populations. Recipient animals  were 
irradiated (250 rad) before adoptive transfer, immunized with MBP/ 
CFA 6 h  after adoptive transfer,  and challenged 8 h  later with 
50/zg OVA. 
Results 
Cognate Recognition Is Not Required for In  Vitro Suppres- 
sion.  We have previously shown suppression of an MBP line, 
when the line was co-incubated with  splenic T  cells from 
an animal orally tolerized to MBP (7). To determine whether 
cell-to-cell contact is required for such in vitro suppression 
to occur,  a transwell  system was  used.  As shown in Table 
1, when irradiated splenocytes from MBP-fed animals were 
incubated together with an MBP line in the lower well, there 
was suppression of proliferation (line 2), while no suppres- 
sion was observed with  splenocytes from PBS fed animals 
(line 3). Virtually identical suppression was observed when 
modulator ceils were separated from responder cells by the 
semipermeable membrane (lines 4 and 5). Thus, suppression 
appears to be mediated by a soluble factor or factors that diffuse 
through  the transwell  membrane. 
In Vitro Suppression Is Triggered  in an Antigen-specific Fashion 
but Is Antigen Nonspecific in its Effect.  To determine whether 
the in vitro suppression observed in the transweU system re- 
quires identical antigen  specificity between modulator and 
responder cells, an OVA line was placed in the lower well. 
As shown in Table 2, modulator cells from MBP-fed animals 
placed in the upper well were able to suppress an OVA line 
in the lower well, in the presence, but not in the absence, 
of MBP (lines 2 and 3). MBP added to modulator cells from 
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Upper well  Lower well  A cpm  Percent  suppression 
1.  -  MBP  line  37,809  _+  3,326  - 
2.-  MBP line  +  MBP-fed modulators  18,412  _+  1,867  51 
3.-  MBP line  +  PBS-fed modulators  34,631  _+  3,994  8 
4.  MBP-fed  modulators  MBP  line  15,620  __  2,294  59 
5.  PBS-fed modulators  MBP line  34,043  _+  3,731  10 
5  x  104 MBP line cells +  MBP (50 #g/ml) were placed in the lower well with 106 irradiated (2,500 rad) thyrnocyte as APC. Splenic modulator 
cells (5  x  105) from MBP- or PBS-fed animals were added to either the upper or lower well. Modulator cells added to the lower well were irradiat- 
ed (1,250 rad). Background counts of the MBP line withut MBP added were between 1,000 and 2,000 cpm. 
Table  2.  Suppression of an OVA  or MBP T  Cell Line by Spleen Cells from MBP- or OVAfed Donors in  Transwell System 
Modulator (upper well)  Responder (lower well)  A cpm  Percent  suppression 
1.-  OVA line  +  OVA  62,761  _+  3,881  - 
2.  MBP-fed  OVA line  +  OVA  65,868  +  3,989  -5 
3.  MBP-fed  +  MBP  OVA line  +  OVA  30,974  +  3,450  51 
4.  PBS-fed  +  MBP  OVA line  +  OVA  61,132  _+  2,967  <1 
5.-  MBP line  +  MBP  71,503  _+  4,581  - 
6.  OVA-fed  MBP line  +  MBP  67,075  _+  2,904  6 
7.  OVA-fed  +  OVA  MBP  line  +  MBP  37,778  +_ 3,780  47 
8.  PBS-fed  +  OVA  MBP line  +  MBP  68,104  _+  4,832  5 
5  x  104 MBP or OVA line cells were placed in the lower 
from MBP-, OVA-, or PBS-fed animals were added to the 
added were between 1,000 and 2,000 cpm. 
well with 106 irradiated (2,500 rad) thymocytes as APC. Modulator cells (5  x  10  s) 
upper well. Background counts of the MBP and OVA lines without MBP or OVA 
animals fed PBS did not suppress the OVA line (line 4). Con- 
versely, suppression of an MBP line was seen with modu- 
lator cells from OVA-fed animals in the presence of OVA (line 
7).  Of note is  that  soluble antigen  added  to the transwell 
in either well diffuses across the membrane and thus is present 
in both wells. 
In Vivo Bystander Suppression.  To determine the relevance 
of the above in vitro bystander suppression  to the in vivo 
situation, a series of experiments were conducted in the EAE 
model.  Rats were fed OVA (1  rag,  five times over a  10-d 
period), then immunized with MBP/CFA in the footpad and 
given OVA 8 h later in the same footpad. As shown in Fig. 
1 A, injecting OVA in the footpad 8 h  after immunization 
with MBP/CFA had no effect on EAE. Mean maximal clin- 
ical disease severity was 3.9  _+  0.2 for MBP/CFA immunized 
and 3.8  _+  0.1  with OVA given subcutaneously.  However, 
if animals were fed OVA before immunization with MBP/CFA 
after which OVA was given subcutaneously in the footpad, 
suppression of EAE occurred in an analogous fashion to feeding 
MBP (Fig. 1 B); disease severity in OVA fed plus OVA given 
subcutaneously is 0.9  _+  0.2, in MBP fed is 1.1  +  0.1,  and 
in the OVA fed and KLH given subcutaneously control group 
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is 3.9  _  0.1  (p <  0.001,  OVA and MBP fed vs.  control). 
No suppression of EAE was observed in animals fed OVA 
in whom KLH was given after MBP/CFA immunization. 
Feeding BSA or KLH had no effect on EAE in animals im- 
munized with MBP/CFA plus OVA subcutaneously (Fig.  1 
C), disease severity is 3.7  _+  0.1 and 3.8  _+  0.2, respectively. 
These experiments demonstrate an in vivo effect similar to 
that seen in vitro in the transwell system. Specifically,  modu- 
lator cells generated by oral tolerization to one antigen can 
suppress  cells  of a  different  antigen  specificity when  the 
tolerizing antigen  is present. 
DTH Responses Associated with In  Vivo Bystander Suppres- 
sion.  We have previously found a correlation between DTH 
responses and the elicitation of suppression of EAE (8).  To 
determine whether a similar correlation existed in the in vivo 
bystander system and to determine the degree of sensitiza- 
tion that occurs in association with the bystander effect, DTH 
responses were measured. Suppressed DTH responses to MBP 
were observed both in animals fed MBP and those fed OVA 
that were subsequently immunized with the MBP/CFA plus 
OVA (Fig.  2).  Oral administration of other antigens,  such 
as KLH or BSA, had no effect on DTH responses to MBP 5 
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Figure 1.  In vivo bystander suppres- 
sion. Lewis rats were fed 1 mg MBP, 
OVA,  BSA,  KLH,  or  1 ml PBS five 
times over a 10-d period then induced 
for EAE as described  in Materials and 
Methods. 8 h  later,  the animals were 
injected subcutaneously with 50/~g of 
OVA or KLH,  in 100 #1 PBS, in the 
same footpad in which primary immu- 
nization  with  MBP/CFA  occurred. 
Clinical signs of EAE were monitored 
as  in  Materials  and  Methods.  Mean 
maximal clinical disease severity for con- 
trol animals fed OVA and given KLH 
subcutaneously was 3.9  +  0.1 vs. 0.9 
_+ 0.2, and 1.1  _+  0.1 for animals fed 
OVA or MBP, respectively (p < 0.001). 
in these animals. Feeding OVA followed by the injection of 
OVA subcutaneously in association with MBP/CFA did not 
generate an immune response to OVA as measured by DTH. 
In Vivo Bystander Suppression Associated witk BSA.  To rule 
out the possibility that something unique to OVA was respon- 
sible for the in vivo bystander suppression observed, similar 
experiments were conducted in which BSA was fed and then 
given  subcutaneously  after  MBP/CFA immunization.  As 
shown in Fig. 3, oral administration  of BSA prior to immu- 
nization with MBP/CFA followed by BSA given subcutane- 
ously suppressed EAE in an analogous fashion as that seen 
with OVA. Of note is that suppression of EAE associated 
with BSA was observed only when the secondary antigen 
was given subcutaneously at a dose of 300/~g, whereas with 
OVA, suppression occurred at a dose of 50/~g. 
Adoptive Transfer of Bystander Suppression.  We have previ- 
ously shown that protection after oral tolerization to MBP 
can  be  adoptively  transferred  by  CD8 +  T  cells (7). As 
shown in Fig. 4, spleen ceils from MBP- or OVA-fed  animals 
adoptively transferred protection into naive recipients, which 
were immunized with MBP/CFA and given OVA subcutane- 
ously. Furthermore, adoptively transferred suppression was 
abrogated by depletion of CD8 +, but not by depletion of 
CD4 § calls. No protection was observed with the adoptive 
transfer of spleen cells from KLH-fed animals to animals im- 
munized with MBP/CFA plus OVA. 
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Figure 2.  DTH responses associated 
with  in  vivo  bystander  suppression. 
DTH responses to MBP and OVA were 
measured 20 d after immunization with 
MBP/CFA  +  OVA in association with 
the  experiment  illustrated  in  Fig.  1. 
Statistical  significance was  calculated 
using the student's t test. Feeding MBP 
or OVA vs. feeding PBS, p  <  0.001. 
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Figure 3.  In vivo bystander suppres- 
sion associated with BSA. BSA, OVA, 
or MBP were fed 1 mg five times over 
a 10-d period, then animals immunized 
with  MPB/CFA  and  8  h  later  chal- 
lenged with 300 #g of BSA, OVA, or 
MBP, respectively, at the site of pfiraary 
immunization. 
FEEDING  TRANSFER 
MBP  + 
MBP  C1)4  DEP 
MBP  CD8  DEP 
OVA  + 
OVA  CD4  DEP 
OVA  CD8  DEP 
KLH  + 
795 
p < 0.001 
p < 0.001 
p < 0.00l 
~p  < 0.001 
i  i  i 
1  2  3 
MEAN  MAXIMAL  CLINICAL  SCORE 
Miller et al. 
? 
4 
Figure  4.  Adoptive  transfer of by- 
stander suppression.  Donor rats were 
fed either 1 mg MBP, OVA, or KLH, 
five times at 2-d intervals, and spleen 
cells were harvested 7-14 d after the final 
feeding and incubated in vitro with the 
homologous antigen (50 #g/ml) for 72 
h before adoptive transfer. Animals were 
immunized with MBP/CFA 6 h  after 
adoptive transfer, and 8 h later were in- 
jected  with  OVA  (50  #g  subcutane- 
ously), as described in Fig. 1. The mean 
maximal severities of EAE for each ex- 
perimental group (five animals/group) 
+  SEM are presented. Discussion 
In the present report, we have begun to define the mecha- 
nism by which cells generated after oral administration of 
antigen suppress immune responses in vitro and induce a form 
of immunological tolerance via active suppression in vivo. 
T  cells generated after induction of oral tolerance are trig- 
gered  in  an  antigen-specific  fashion  and  release  antigen 
nonspecific factors that mediate suppression. We have termed 
this mechanism "antigen-driven bystander suppression". By- 
stander inflammatory immunologic processes have been de- 
scribed both for EAE and in animal models of arthritis. By- 
stander central nervous system inflammation occurs in animals 
sensitized to purified protein derivative (PPD) by immuniza- 
tion with PPD (17) or inoculation with PPD lines when PPD 
is injected into the brain (18). Similarly, bystander arthritis 
can be induced by active immunization with various antigens 
followed by intra-articular  challenge with the specific antigen 
(19-21). Our results are the first demonstration of a bystander 
immunologic process that suppresses or downregulates an 
autoimmune inflammatory response rather than enhances it. 
Bystander suppression of EAE does not appear to be related 
to the generation of a competing immune response to OVA, 
as no DTH responses to OVA develop in vivo after either 
feeding or subcutaneous injection of OVA in PBS. Moreover, 
adoptive transfer experiments demonstrate bystander suppres- 
sion involves an active mechanism mediated by antigen-specific 
CD8 + cells. Gautam and Glynn (22) reported that emul- 
sifying OVA with MBP in CFA suppressed EAE by inhibiting 
activation of MBP-specific T cells, presumably by competi- 
tion for antigen presentation. We observed no inhibition of 
EAE when OVA was given subcutaneously in PBS, 8 h after 
immunization with MBP/CFA.  Furthermore, in vivo by- 
stander suppression of EAE is not unique to OVA, as we have 
observed similar suppression with another antigen (BSA) tested 
in this fashion. 
Oral tolerance to autoantigens is both disease and antigen 
specific. Feeding MBP suppresses EAE but does not affect 
experimental autoimmune uveitis or adjuvant arthritis (10, 
11). Similarly, feeding type II collagen suppresses arthritis 
models but not EAE (11, 23,  24). Thus, the secretion and 
action of antigen-nonspecific factors by regulatory cells in- 
duced by oral tolerance must occur in the local microenviron- 
ment of the lymphoid tissue where the immune response is 
generated, along migratory pathways of the effector  cells 
and/or at the inflamed site in the target organ where the au- 
toantigen is present. Studies are currently in progress to fur- 
ther elucidate the temporal sequence and location of these 
interactions between regulatory and effector cells. Of note 
is that transfer of serum from orally tolerized animals does 
not affect immune responses or EAE (unpublished data), in- 
dicating that the antigen-nonspecific factors released by modu- 
lator cells from orally tolerized animals do not appear to be 
acting systemically. 
Several cytokines exert  suppressive  activity on different 
aspects of the immune responses  such as cell proliferation, 
differentiation,  and  the  production and  release  of other 
cytokines (25). The factor released by T cells that mediates 
the immunosuppression  after oral tolerization, both in vitro 
and in vivo, appears to be related  to transforming growth 
factor 13 (TGF-~), or a member of the TGF-B family. In re- 
cent experiments, we have found the abrogation of suppres- 
sion by culture supernatants of modulator cells and the abro- 
gation  of oral  tolerance to  MBP  in  the  EAE  model by 
anti-TGF-/~ neutralizing antibodies (26,  and Miller,  A., A. 
Roberts, M. Sporn, O. Lider, and H. L. "~t'einer, manuscript 
submitted for publication). 
The in vivo bystander suppression we have described may 
have implications for the treatment of other autoimmune dis- 
eases by oral tolerization. We have previously found that oral 
administration of collagen type II suppresses adjuvant arthritis 
(11). Given our present results, it may be that the mechanism 
for such suppression relates to the generation of collagen- 
specific suppressor cells that are generated by feeding and that 
migrate to the joint where they are triggered by collagen to 
release antigen-nonspecific suppressor cytokines. We have also 
recently found suppression of diabetes in the NOD mouse 
by oral administration of insulin, even though there is no 
dear evidence that autoreactivity to insulin is involved in the 
pathogenesis of diabetes in the NOD mouse (27). Thus, the 
treatment of an organ-specific  autoimmune disease by oral 
tolerization may not require knowledge of the inciting au- 
toantigen, only the oral administration of an autoantigen from 
the target organ. 
Although the mechanisms by which active suppression leads 
to immunologic unresponsiveness are not completely under- 
stood, our findings suggest that a common mechanism may 
exist among different systems. The characteristics of the cells 
that mediate active suppression induced by oral tolerance de- 
scribed in this report are similar to those described in human 
lepromatous leprosy (27),  in which CD8 + suppressor cell 
clones are triggered in an antigen-specific fashion, but mediate 
suppression via an as yet unidentified antigen-nonspecific mech- 
anism. Other forms of antigen-driven peripheral tolerance 
have been described in the EAE model, including autoan- 
tigen given intravenously (28)  or  coupled to  splenocytes 
(28-30), and a form of bystander suppression has also been 
described using haptens (32). Whether the mechanisms un- 
derlying these forms of antigen-driven suppression are similar 
to the immunological mechanisms of oral tolerance is yet to 
be defined. 
In summary, our results further characterize  the mecha- 
nism of action of CD8 + cells generated after oral toleriza- 
tion, and may provide a paradigm to understand the mecha- 
nism by which active suppression participates in the generation 
of tolerance to autoantigens. 
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